sun pharma to acquire dusa pharmaceuticals

Sun Pharma to Acquire DUSA Pharmaceuticals

Note: DUSA’s Levulan combination therapy is approved by FDA for treatment of non-hyperkeratotic actinic keratoses or AKs of the face or scalp. Additionally, DUSA’s BLU-U® treatment has been approved by FDA for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions. Levulan is manufactured by DUSA in its FDA approved facility at Wilmington, MA.

Now take a look at this passage from an old Bell Potter Report (page 26)...

There is the potential to target TPM/diclofenac to actinic keratosis as a first market opportunity

Another well known topical diclofenac product on the market is Solaraze, whose main indication is treatment of a skin condition called actinic keratosis (AK). Currently POH sees TPM/diclofenac’s primary potential as lying in the AK space, with a general NSAID product to follow later:

• Typically Solaraze and competitor products like Aldara100 or Efudex101 are slow working and result in the skin getting red and raw, leading to poor compliance rates. By contrast TPM’s anti-inflammatory properties would allow it to be positioned as a superior product in the AK space in terms of lower dosages required. This points to potentially lower trial numbers on the part of TPM/diclofenac in order to demonstrate superior patient outcomes.

• The market is solid. Around 5-6 million physician office visits a year in the US are generated

Bell Potter Report